Skip to main content

Eli Lilly CEO says Medicare price negotiations could harm drug development

Ricks said the "biggest problem" with the IRA provision stems from a difference in timeline for negotiating prices on two different types of drugs.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.